optaflu
seqirus gmbh - virus influence površinskih antigenov (haemagglutinin in neuraminidase), inaktivirano, naslednjih vrst:a/california/7/2009 (h1n1)pdm09 - kot sev(a/brisbane/10/2010, divji tip)a/Švica/9715293/2013 (h3n2) - kot sev(a/južna avstralija/55/2014, divji tip)b/phuket/3073/2013–kot sev(b/utah/9/2014, divji tip) - influenza, human; immunization - cepiva - preprečevanje influence za odrasle, zlasti pa pri tistih, ki vodijo povečano tveganje za zaplete, povezane. optaflu je treba uporabljati v skladu z uradnimi smernice.
fsme immun 0,5 ml suspenzija za injiciranje v napolnjeni injekcijski brizgi
pfizer luxembourg sarl - virus klopnega meningoencefalitisa, inaktivirani - suspenzija za injiciranje - virus klopnega meningoencefalitisa, inaktivirani 2,4 µg / 0,5 ml - cepivo proti klopnemu meningoencefalitisu z inaktiviranimi virusi
fsme immun 0,5 ml suspenzija za injiciranje v napolnjeni injekcijski brizgi
pfizer luxembourg sarl - virus klopnega meningoencefalitisa, inaktivirani - suspenzija za injiciranje - virus klopnega meningoencefalitisa, inaktivirani 2,4 µg / 0,5 ml - cepivo proti klopnemu meningoencefalitisu z inaktiviranimi virusi
formel 20 mg/15 ml sirup
pliva ljubljana d.o.o., ljubljana - dekstrometorfanijev bromid - sirup - dekstrometorfanijev bromid 20 mg / 1 ml - dekstrometorfan
formel 20 mg/15 ml sirup
pliva ljubljana d.o.o., ljubljana - dekstrometorfanijev bromid - sirup - dekstrometorfanijev bromid 20 mg / 15 ml - dekstrometorfan
flucelvax tetra
seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - gripa, človek - gripi, inaktivirano, split virus ali površinski antigen - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra je treba uporabljati v skladu z uradnimi priporočili.
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
purevax rcpch felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
zutectra
biotest pharma gmbh - humani hepatitis b imunoglobulin - immunization, passive; hepatitis b; liver transplantation - imunski sera in imunoglobulini, - preprečevanje ponovne okužbe z virusom hepatitisa b (hbv) pri hbsag in hbv-dna negativnih odraslih bolnikih, vsaj en teden po presaditvi jeter za hepatitis b, povzročeno z odpovedjo jeter. negativni status hbv-dna je treba potrditi v zadnjih 3 mesecih pred olt. bolniki morajo biti pred začetkom zdravljenja hbsag negativni. sočasno uporabo ustrezne virostatic agentov, je treba šteti kot standard hepatitisa b ponovno okužbo profilakso.
bovela
boehringer ingelheim vetmedica gmbh - spremenjeno živo govedo virusne driske virus tipa 1, non-cytopathic staršev sev ke-9 in spremenjen živo govedo virusne driske virus tipa 2, ki niso cytopathic staršev sev ny-93 - immunologicals za bovidae, Živo virusna cepiva - za aktivno imunizacijo goveda (od 3 mesecev starosti za zmanjšanje hyperthermia in za zmanjšanje zmanjšanje leukocyte count zaradi goveja virusne driske virus (bvdv-1 in bvdv-2), in za zmanjšanje virus prelivanje in viraemia zaradi bvdv-2. za aktivno imunizacijo goveda proti bvdv-1 in bvdv-2, da se prepreči rojstvo vztrajno okuženih teleta, ki jih povzročajo okužbe transplacental.